Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension
Authors:
Open Access
- 18 January 2022
- journal article
- review article
- Published by Wiley in Pulmonary Circulation
- Vol. 12 (1) , e12028
Abstract
Pulmonary hypertension (PH) is a highly morbid condition. PH due to left heart disease (PH‐LHD) has no specific therapies and pulmonary arterial hypertension (PAH) has substantial residual risk despite several approved therapies. Multiple lines of experimental evidence link metabolic dysfunction to the pathogenesis and outcomes in PH‐LHD and PAH, and novel metabolic agents hold promise to improve outcomes in these populations. The antidiabetic sodium–glucose cotransporter 2 (SGLT2) inhibitors and glucagon‐like peptide‐1 (GLP1) agonists targeting metabolic dysfunction and improve outcomes in patients with LHD but have not been tested specifically in patients with PH. The angiotensin receptor/neprilysin inhibitors (ARNIs) produce significant improvements in cardiac hemodynamics and may improve metabolic dysfunction that could benefit the pulmonary circulation and right ventricle function. On the basis of promising preclinical work with these medications and clinical rationale, we explore the potential of SGLT2 inhibitors, GLP1 agonists, and ARNIs as therapies for both PH‐LHD and PAH.Keywords
This publication has 198 references indexed in Scilit:
- Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exerciseDiabetes, Obesity and Metabolism, 2013
- Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytesJournal of Clinical Investigation, 2012
- Unrecognized glucose intolerance is common in pulmonary arterial hypertensionThe Journal of Heart and Lung Transplantation, 2011
- Characteristics of Interstitial Fibrosis and Inflammatory Cell Infiltration in Right Ventricles of Systemic Sclerosis-Associated Pulmonary Arterial HypertensionInternational Journal of Rheumatology, 2010
- Atrial natriuretic peptide suppresses endothelin gene expression and proliferation in cardiac fibroblasts through a GATA4-dependent mechanismCardiovascular Research, 2009
- Pulmonary Hypertension in Heart Failure With Preserved Ejection FractionJACC, 2009
- Synergy between Natriuretic Peptides and Phosphodiesterase 5 Inhibitors Ameliorates Pulmonary Arterial HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1Proceedings of the National Academy of Sciences, 2008
- Pulmonary arterial remodeling induced by a Th2 immune responseJournal of Experimental Medicine, 2008
- Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routineHeart, 2005